« Return to News | Study Conduct

IOM to develop consensus study on strategies for sharing clinical trial data

Wednesday, April 10, 2013 09:46 AM

The Institute Of Medicine (IOM) plans to follow up on its recent workshop, Sharing Clinical Research Data, by developing a consensus study on strategies for sharing clinical trial data.

As discussed at the workshop, the benefits of sharing data, including the identification of new drug targets, validating targets, identifying new indications for use and enhancing safety and efficacy are increasingly recognized by drug developers, regulators, patient groups, medical journals and providers. This realization has moved the conversation around clinical trial data sharing from whether it should occur, to how it can be enabled. As data holders are beginning to individually generate policies for clinical trial data access, better alignment among stakeholder actions will be necessary to harness the full potential of data sharing.

The IOM is currently organizing a planning activity that will focus on developing an independent consensus study that would provide guidance on the responsible sharing of clinical trial data. A small planning meeting for potential sponsors and key stakeholders will be held in the near future.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.